Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets
once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and
additional in sputum and blood serum. Also data on safety status will be obtained.
Patients to be included required to have moderate to severe COPD associated with chronic
bronchitis. The total duration of this randomized, multicentre, phase III trial is 24 weeks
maximum.